PPT1 / Palmitoyl-protein thioesterase 1 · IHC design guide

Design Immunohistochemistry for PPT1

Plan PPT1 staining in paraffin sections using the reported lysosomal tissue profile and high-staining cell types (HPA tissue IHC). The catalog antibody has an IHC-P dilution range of 0.5–1 μg/mL (datasheet M02690).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for PPT1 (IHC for PPT1): expected localisation General lysosomal expression in tissue IHC (HPA tissue IHC), antibody M02690, validated IHC image, and IHC protocol steps — Printable **PPT1** IHC protocol sheet — expected localisation General lysosomal expression in tissue IHC (HPA tissue IHC), antibody M02690, controls and protocol steps. Open the full PPT1 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

PPT1 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	General lysosomal expression in tissue IHC (HPA tissue IHC)
	Staining pattern	High in glandular, ciliated and glial cells; lysosomal (HPA tissue IHC)
	Antigen retrieval	EDTA pH 8.0 HIER, heat-mediated (datasheet M02690)
	Positive control ⓘ	Adrenal gland+4 more · see all
	Negative control ⓘ	Adipose tissue+3 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections (standard IHC practice; not target-specific)
	Caveat	Secreted PPT1 may complicate cellular attribution (UniProt)
	Regulation	No expression regulator reported (UniProt)
	Isoform / epitope	2 isoforms; epitope differences unreported (UniProt)

Section 1

Recommended PPT1 IHC & IF Protocols

The catalog antibody’s IHC-P protocol is paired with published PPT1 staining methods for oral squamous cell carcinoma, hepatocellular carcinoma, and Ewing sarcoma specimens (PMC12767243; PMC10314632; PMC12355353).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human intestinal cancer tissue; fixative not specified (datasheet M02690)
Fixation	Image fixative and duration unreported (datasheet M02690); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: EDTA pH 8.0 (datasheet M02690); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet M02690)
Primary antibody	Mouse monoclonal (clone 10F3) anti-PPT1, 0.5-1μg/ml (datasheet M02690)
Primary incubation	Overnight at 4 °C (datasheet M02690)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet M02690)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	PPT1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: General lysosomal expression. No signal in the no-primary control.

💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval for the catalog antibody (datasheet M02690). The oral squamous cell carcinoma study used microwave Tris–EDTA pH 9.0 (PMC12767243).

Section 2

What Is the Expected PPT1 Staining Pattern?

PPT1 should show mainly cytoplasmic staining compatible with lysosomal distribution, with Golgi and vesicular localisation also supported by IF imaging (UniProt P50897 subcellular; HPA: general lysosomal expression; HPA: Golgi apparatus and vesicles supported). HPA reports high IHC staining in selected glandular, ciliated and glial cells, against a broader low tissue-specificity profile (HPA: tissue IHC). Treat the pattern as supported evidence with medium antibody–RNA consistency (HPA: reliability Supported). PPT1 has no transmembrane segment (UniProt P50897 topology).

What am I looking at on my slide?
Granular cytoplasmic signal in adrenal or breast glandular cells, or in bronchial ciliated cell bodies.	These are listed high-staining cell populations (HPA: tissue IHC). Cytoplasmic granularity is compatible with PPT1's lysosomal distribution (UniProt P50897 subcellular). Chromogenic IHC alone cannot identify individual organelles; interpret the compartment alongside tissue structure and controls (general IHC practice).
Predominantly crisp nuclear staining, or a continuous cell-surface outline without cytoplasmic signal.	These patterns do not fit the reported lysosomal, Golgi and vesicular locations (UniProt P50897 subcellular; HPA: ICC-IF). Recheck morphology, background and antibody controls before calling them PPT1-specific; the compartment mismatch raises concern but does not establish its cause (general IHC practice).
Strong staining in adipocytes or oral-mucosal squamous epithelial cells while listed high-staining cells are weak.	HPA reports PPT1 as not detected in those particular cell populations, and high in several glandular, ciliated and glial populations (HPA: tissue IHC). The reversal warrants investigation for cross-reactivity or endogenous chromogen-generating activity; it does not prove either mechanism (general IHC practice).
Diffuse colour across tissue and cell-free regions, obscuring cell boundaries and cytoplasmic detail.	A broad deposit cannot establish the expected cell-restricted, cytoplasmic pattern (HPA: tissue IHC; UniProt P50897 subcellular). Check a no-primary control and the detection/background-blocking steps to distinguish antibody-associated signal from background generated by the IHC workflow (general IHC practice).
No convincing cytoplasmic signal in an intact region of adrenal glandular cells or bronchial ciliated cell bodies.	Those cell types have high reported staining, so a blank section merits a technical review (HPA: tissue IHC). Confirm cell identity and tissue preservation, then inspect antibody use, retrieval settings and chromogen development; a listed high category does not guarantee every specimen will stain (general IHC practice).

💡Expected PPT1 appearanceCall positive a cell-associated, predominantly granular cytoplasmic signal in a listed high-staining population, such as adrenal glandular or bronchial ciliated cells (HPA: tissue IHC; UniProt P50897 subcellular); dominant nuclear, cell-surface or tissue-wide colour is discordant and should be checked against controls (HPA: ICC-IF; general IHC practice).

How each factor affects the staining
Compartment resolution	UniProt lists lysosome, secreted, Golgi and endoplasmic-reticulum locations; HPA IF supports Golgi and vesicles (UniProt P50897 subcellular; HPA: ICC-IF). A chromogenic cytoplasmic deposit is consistent with these locations but cannot assign its source to a specific organelle (general IHC practice).
Cell-type context	High staining occurs in selected glandular, ciliated and glial cells; adipocytes and some squamous epithelial cells are listed as not detected (HPA: tissue IHC). Compare the named cells within a section: HPA's low tissue specificity is not a prediction of uniform staining across every cell type (HPA: tissue IHC).
Processing and extracellular signal	PPT1 has a signal peptide at residues 1–27 and a mature chain at 28–306; UniProt also lists secretion and no transmembrane segment (UniProt P50897 processing, topology and subcellular). These facts do not predict a specific extracellular IHC pattern or establish whether this antibody recognises precursor or mature PPT1.
Strength of pattern evidence	The listed IHC pattern has Supported reliability, described as medium antibody–RNA consistency; HPA021546 is Supported for IHC and ICC (HPA: tissue IHC reliability; HPA: antibody validation). Use the pattern to guide interpretation, while treating discordant compartments or cell types as findings to check with controls.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
A listed high-staining cell population shows no signal.	Cell identification, antibody or detection performance, and specimen condition are possible issues; the HPA high category is a reported pattern, not a specimen-level guarantee (HPA: tissue IHC; general IHC practice).	Confirm the named cells are present, then review the catalog antibody's IHC-P instructions and a working positive-control section; assess retrieval and development as general workflow variables without assuming PPT1-specific fixation sensitivity (general IHC practice).
The entire section has heavy brown background.	Diffuse deposition can arise from nonspecific antibody binding or endogenous activity in a chromogenic detection workflow (general IHC practice). It is inconsistent with a readable cell-associated PPT1 pattern (HPA: tissue IHC).	Examine a no-primary control, review blocking and washes, and check any endogenous-enzyme block appropriate to the detection chemistry; score cell-specific staining only after background is controlled (general IHC practice).
Adipocytes stain strongly despite weak staining in listed high populations.	Adipocytes are reported as not detected, so the distribution raises concern for cross-reactivity or detection background; HPA staining alone cannot identify which cause applies (HPA: tissue IHC; general IHC practice).	Verify the stained cells morphologically and compare antibody-treated and no-primary sections. Reassess specificity only after a listed high-staining cell population and the background controls can be read together (HPA: tissue IHC; general IHC practice).
Signal appears mainly nuclear or as a sharp plasma-membrane rim.	That dominant pattern conflicts with the reported intracellular locations and lack of a transmembrane segment (UniProt P50897 subcellular and topology; HPA: ICC-IF).	Check counterstain and cell boundaries, then compare controls and cytoplasmic staining in a listed high population before assigning the colour to PPT1 (HPA: tissue IHC; general IHC practice).
Granules are visible, but their organelle identity is uncertain.	PPT1 has several reported intracellular locations, and chromogenic IHC does not resolve organelle identity on its own (UniProt P50897 subcellular; HPA: ICC-IF; general IHC practice).	Describe the observed staining as granular cytoplasmic and report the cell type and intensity. Reserve a lysosomal or Golgi assignment for evidence with suitable subcellular resolution (general IHC practice).
IF/ICC Q&A: where should PPT1 fluorescence appear?	HPA supports Golgi apparatus and vesicular localisation in ICC-IF, with images from A-431 and U2OS cells (HPA: ICC-IF). This evidence describes IF localisation, not a chromogenic IHC protocol.	Expect intracellular Golgi and vesicular signal when interpreting IF/ICC images; use the separate IF/ICC guide for experimental setup (HPA: ICC-IF).

Source: UniProt P50897 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing PPT1 staining

IHC analysis of PPT1 using anti PPT1 antibody (M02690). PPT1 was detected in paraffin-embedded section of human intestinal cancer tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml mouse anti-PPT1 Antibody (M02690) overnight at 4°C. Biotinylated goat anti-mouse IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC) (Catalog # SA1021) with DAB as the chromogen.

M02690 · IHCIHC analysis of PPT1 using anti PPT1 antibody (M02690). PPT1 was detected in paraffin-embedded section of human intestinal cancer tissue. He

IHC analysis of PPT1 using anti PPT1 antibody (M02690). PPT1 was detected in paraffin-embedded section of human lung cancer tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml mouse anti-PPT1 Antibody (M02690) overnight at 4°C. Biotinylated goat anti-mouse IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC) (Catalog # SA1021) with DAB as the chromogen.

M02690 · IHCIHC analysis of PPT1 using anti PPT1 antibody (M02690). PPT1 was detected in paraffin-embedded section of human lung cancer tissue. Heat med

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000131238-PPT1/tissue/cerebral+cortex#imid_5775660

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000131238-PPT1/tissue/colon#imid_5775594

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000131238-PPT1/tissue/liver#imid_5775587

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000131238-PPT1/tissue/kidney#imid_5775596

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA021546; green = PPT1, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for PPT1 IHC & IF

🧪Run breast first: glandular cells should stain (HPA: High in breast glandular cells). Use adipose tissue as the negative tissue (HPA: Not detected in adipocytes); adipocytes within the breast section, where present, should lack specific staining and provide an internal background reference (HPA: Not detected in adipocytes).

Positive control tissue: Adrenal gland (Glandular cells, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show PPT1 in A-431, U2OS, with annotated localisation: Golgi apparatus (supported), Vesicles (supported) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only slide; a matched mouse IgG isotype control, with clonality matched where applicable (selected M02690 caption: mouse anti-PPT1); and PPT1-knockout material as a biological negative. Block endogenous peroxidase and check endogenous biotin background when using the caption’s avidin–biotin/DAB detection method (selected M02690 caption: SABC with DAB; standard IHC practice).

⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the exact M02690 tissue-IHC caption does not state a fixative (selected M02690 caption: fixative not stated). The caption uses heat retrieval in EDTA at pH 8.0, but does not establish that retrieval is required for every specimen (selected M02690 caption: heat-mediated EDTA retrieval). The supplied evidence does not establish that frozen sections or IF are easier; for the breast positive slide, assess biotin background when using SABC detection (selected M02690 caption: SABC with DAB; standard IHC practice).

HPA tissue IHC evidence for PPT1

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Adrenal gland	Glandular cells	High	Protein (IHC)	HPA →
Breast	Glandular cells	High	Protein (IHC)	HPA →
Bronchus	Ciliated cells (cell body)	High	Protein (IHC)	HPA →
Caudate	Glial cells	High	Protein (IHC)	HPA →
Cerebellum	Bergmann glia - cytoplasm/membrane	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Cervix	Glandular cells	Not detected	Protein (IHC)	HPA →
Oral mucosa	Squamous epithelial cells	Not detected	Protein (IHC)	HPA →
Vagina	Squamous epithelial cells	Not detected	Protein (IHC)	HPA →

Section 3

Advanced PPT1 IHC Tips

Troubleshoot PPT1 staining in paraffin sections by checking retrieval, cellular pattern, controls, and scoring before interpreting chromogenic signal.

What retrieval should I try when PPT1 staining is weak in paraffin sections?

Start with heat-mediated antigen retrieval in EDTA at pH 8.0 (datasheet M02690). The selected paraffin-section image used that retrieval before 1 μg/ml primary antibody overnight at 4°C (datasheet M02690). If staining remains weak, compare a second retrieval condition on adjacent sections while keeping antibody concentration and detection constant; treat it as an optimization experiment, not a validated PPT1 condition (standard IHC practice). Include a known positive tissue compartment and a no-primary control so increased signal can be distinguished from increased background (standard IHC practice). Record heating, cooling, and section integrity for each condition because damaged morphology makes a stronger stain difficult to interpret (standard IHC practice).

Could fixation explain inconsistent PPT1 staining between paraffin blocks?

Target-specific fixation sensitivity is unknown: the selected PPT1 paraffin-section caption does not state its fixative (datasheet M02690). Do not infer fixation tolerance from tissue staining patterns or PPT1 processing annotations (HPA tissue IHC; UniProt P50897). Compare blocks with documented fixation histories using the same EDTA pH 8.0 retrieval, antibody concentration, and detection run (datasheet M02690; standard IHC practice). Examine morphology and the staining of a positive control before assigning a weak result to PPT1 loss (standard IHC practice). If fixation history differs, report that limitation alongside the stain rather than treating differences in intensity as biological variation (standard IHC practice).

Where should convincing PPT1 chromogenic signal appear within cells?

Expect predominantly intracellular, punctate or perinuclear cytoplasmic staining consistent with PPT1 lysosomal and Golgi annotations (UniProt P50897 subcellular; HPA subcellular). The subcellular atlas supports Golgi and vesicular localisation, while UniProt also lists secretion and endoplasmic reticulum localisation (HPA subcellular; UniProt P50897 subcellular). At the tissue level, high staining is reported in bronchial ciliated cell bodies and cerebral cortex glia (HPA tissue IHC). Assess the pattern within identifiable cells under adequate counterstain, using neighbouring negative areas to judge diffuse pigment (standard IHC practice). Strong nuclear-only staining or uniform extracellular deposits warrant a specificity check before being called PPT1 (UniProt P50897 subcellular; standard IHC practice).

How could epitope placement change what the PPT1 stain detects?

PPT1 has 2 annotated isoforms, and its precursor has a signal peptide at residues 1–27 followed by a chain beginning at residue 28 (UniProt P50897). Three glycosylation sites are annotated at residues 197, 212, and 232 (UniProt P50897). The supplied product caption does not identify the antibody epitope, so staining cannot establish which isoform or processing state it recognizes (datasheet M02690; UniProt P50897). If an epitope map becomes available, check whether it lies in a sequence shared by both isoforms and within the processed chain (standard IHC practice). Until then, describe the result as PPT1 immunoreactivity, and use independent specificity evidence for claims about variants or processing (standard IHC practice).

How can IF help check a PPT1 pattern seen by chromogenic IHC?

Use IF as a separate corroborating experiment for the chromogenic cell pattern, with a marker for the cell type being examined, such as glia where tissue IHC reports high PPT1 staining (HPA tissue IHC; standard IF practice). Choose spectrally separated fluorophores and inspect an unstained section for tissue autofluorescence before assigning faint puncta to PPT1 (standard IF practice). Permeabilise sufficiently to expose intracellular PPT1, while recognizing that its precise antibody epitope and membrane sidedness are unreported; PPT1 has no transmembrane segment (UniProt P50897 topology; datasheet M02690). Compare cell identity and cytoplasmic distribution with the IHC section, and include single-label controls to identify bleed-through (HPA subcellular; standard IF practice).

What should I check if PPT1 DAB staining is widespread?

First compare a no-primary section with the PPT1 section to identify signal from detection reagents or tissue pigments (standard IHC practice). The selected image used a biotinylated secondary, streptavidin–biotin complex, and DAB, so endogenous biotin and peroxidase are relevant background checks for that workflow (datasheet M02690; standard IHC practice). Apply a peroxidase block and assess whether additional biotin blocking is needed, then compare with an alternative detection system if background persists (standard IHC practice). The caption used 10% goat serum blocking and 1 μg/ml primary antibody; use those as documented starting conditions rather than evidence of universal optimal settings (datasheet M02690). Judge residual stain against cell morphology and the expected cytoplasmic distribution (UniProt P50897 subcellular; standard IHC practice).

How should I score PPT1 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and compartment before scoring, because PPT1 staining varies by cell type in the tissue atlas (HPA tissue IHC). For a defined population, record the percentage of positive cells and staining intensity, then calculate an H-score on a 0–300 scale if intensity grading is reproducible (standard IHC practice). For punctate staining, an area or positive-cell density per mm² can supplement the score, provided identical thresholds are applied across sections (standard IHC practice). Normalize counts to the number of evaluable cells or tissue area within the same annotated compartment, excluding folds, edges, and necrotic regions (standard IHC practice). Report background correction, field selection, and the positive threshold so comparisons can be reproduced (standard IHC practice).

When should a positive PPT1 stain be considered artefactual?

A credible result places PPT1 signal in identifiable cells with a cytoplasmic distribution compatible with lysosomes, Golgi, or vesicles (UniProt P50897 subcellular; HPA subcellular). Check cell identity: high staining is reported in adrenal glandular cells and caudate glia, whereas adipocytes are listed as not detected (HPA tissue IHC). Distrust staining confined to section edges, folds, or necrotic areas, especially when it lacks comparable signal in intact cells (standard IHC practice). A no-primary control can reveal endogenous peroxidase or biotin-related signal in the DAB detection workflow used for the selected image (datasheet M02690; standard IHC practice). Interpret any remaining discrepancy alongside morphology and control sections before calling it altered PPT1 expression (standard IHC practice).

Boster reagents

Best PPT1 / Palmitoyl-protein thioesterase 1 IHC Antibodies

Both antibodies have human paraffin-section IHC images (catalog image captions: M02690, PB9781). PB9781 also lists human ICC, with no IF image supplied (catalog: applications and image captions).

Real IHC data

Anti-PPT1 Antibody ® (monoclonal, 10F3)

Cat # M02690

View product →

M02690 is human-reactive and has paraffin-section IHC images from human intestinal, lung, and mammary cancer tissue (catalog: reactivity and M02690 image captions). PB9781 lists human IHC and ICC, and its IHC image shows human intestinal cancer tissue in a paraffin section (catalog: applications and PB9781 image caption).

Which to pick: For human paraffin-section IHC, choose M02690 for a mouse monoclonal with three documented tissue examples, or PB9781 for a rabbit antibody with one documented tissue example (catalog: host, clone 10F3, and each SKU’s IHC image captions). For ICC, choose PB9781 because ICC is listed for human samples; neither product supplies an IF image here (catalog: PB9781 application listing and both products’ IF image fields). PB9781 lists mouse and rat reactivity, but its paraffin-section IHC listing and image are human only; the fixative is unreported in both IHC captions (catalog: PB9781 dilution listing, reactivity, and both SKUs’ IHC image captions).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry P50897 (PPT1_HUMAN, Palmitoyl-protein thioesterase 1).
Human Protein Atlas. PPT1 tissue IHC expression (reliability: Supported).
Human Protein Atlas. PPT1 subcellular location (ICC-IF): Localized to the Golgi apparatus and vesicles..
Human Protein Atlas. PPT1 antibody validation summary (1 antibodies).
High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma. Cancer cell international 2022 — PMC8917761.
Evaluating palmitoyl-protein thioesterase 1 in oral squamous cell carcinoma: A novel indicator of tumor behavior and therapeutic response. World journal of experimental medicine 2025 — PMC12767243.
Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma. Journal for immunotherapy of cancer 2023 — PMC10314632.
A prognostic model correlated with fatty acid metabolism in Ewing's sarcoma based on bioinformatics analysis. Open medicine (Warsaw, Poland) 2025 — PMC12355353.
PubMed PMID:7637805 — UniProt-cited evidence.
PubMed PMID:8633062 — UniProt-cited evidence.
PubMed PMID:8786130 — UniProt-cited evidence.